Short-term intravenous interferon therapy for chronic hepatitis B

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis B (CHB) remains a significant global health concern.
• Current interferon (IFN) therapies for CHB often require prolonged treatment durations.
• Optimizing IFN treatment regimens for improved efficacy and patient compliance is crucial.

Purpose of the Study:

• To evaluate the therapeutic efficacy of a short-term, multiple daily dosing regimen of intravenous interferon-beta (IFN-beta) in HBeAg-positive CHB patients.
• To compare the outcomes of this novel regimen with conventional IFN therapies.

Main Methods:

• Twenty-six HBeAg- and HBV-DNA-positive CHB patients received intravenous IFN-beta (102 million international units) over 28 days.
• The dosing schedule involved multiple administrations daily, increasing over the treatment period.
• Patients were monitored for 24 weeks post-treatment.

Main Results:

• Six months post-treatment, 50% of patients achieved HBV-DNA loss, and 34.6% lost HBeAg.
• HBeAg seroconversion occurred in 30.8% of patients, with 38.5% developing anti-HBe.
• Alanine aminotransferase (ALT) normalization was observed in 42.0% of patients.

Conclusions:

• A 4-week intravenous IFN-beta regimen demonstrated therapeutic effects comparable to longer IFN-alpha or pegylated-IFN-alpha (peg-IFN) treatments.
• This shorter treatment duration, coupled with potentially fewer adverse effects, suggests improved patient quality of life.
• The multiple dosing enabled by the intravenous route may contribute to the enhanced efficacy of IFN-beta.